biote (BTMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting will be held virtually on May 12, 2026, with stockholders able to participate, vote, and ask questions online.
Stockholders of record as of March 23, 2026, are eligible to vote on the election of two Class I directors and the ratification of the independent auditor.
The Board recommends voting for both director nominees and for the ratification of Deloitte & Touche LLP as auditor.
Proxy materials and the annual report are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Proposal 1: Election of Andrew R. Heyer and Dana Jacoby as Class I directors to serve until 2029.
Proposal 2: Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026.
Board recommends voting for both proposals; director elections require a plurality, auditor ratification requires a majority of votes cast.
Stockholder proposals for the 2027 meeting must be received by December 3, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The Board consists of seven members divided into three classes with staggered terms.
Majority of directors are independent; only the Chairman and CEO are not independent.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
Lead independent director role established to enhance board independence.
Board and committees met regularly in 2025, with high attendance rates.
Latest events from biote
- Vote on two director nominees and auditor ratification at the May 2026 annual meeting.BTMD
Proxy filing2 Apr 2026 - 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMD
Q4 202511 Mar 2026 - Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMD
Q2 20242 Feb 2026 - Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 revenue up 12.8% to $51.4M; guidance trimmed amid software and hurricane impacts.BTMD
Q3 202414 Jan 2026 - Q4 revenue up 9%, margin gains, and 2025 outlook projects further growth and profitability.BTMD
Q4 202426 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with robust governance in place.BTMD
Proxy Filing2 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with board-backed nominees.BTMD
Proxy Filing2 Dec 2025 - Virtual meeting to elect two directors and ratify auditor, with board support for all proposals.BTMD
Proxy Filing2 Dec 2025